Illumina Inc. (ILMN)

ILMN's latest software features easy-to-use oncology apps, enhanced multiomics pipelines and AWS F2 support, enabling faster turnaround times.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Signios Biosciences (“Signios Bio”), a science-first biotechnology company leading in multiomics and AI-powered bioinformatics, in collaboration with Illumina, an...

Carl Icahn is making bold moves from the lab to the tarmac.

Review Illumina's (ILMN) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

Illumina, Inc. ILMN reported upbeat earnings for the first quarter, but lowered its FY25 guidance, after the closing bell on Thursday.

Illumina faces significant challenges, including revenue declines, margin pressures, and geopolitical hurdles, notably from China and competition from Roche's SBX technology. Q1 2025 results were in l...

ILMN delivers better-than-expected earnings and revenues in the first quarter of 2025.

Illumina, Inc. (NASDAQ:ILMN ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Brian Blanchett - Interim Head of Investor Relations Jacob Thaysen - Chief Executive Officer ...

Although the revenue and EPS for Illumina (ILMN) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street...

Illumina (ILMN) came out with quarterly earnings of $0.97 per share, beating the Zacks Consensus Estimate of $0.96 per share. This compares to earnings of $0.09 per share a year ago.